Nvidia announces partnership with GSK focused on drug discovery

/ / News

Nvidia Corp. shares are up 3% in Monday trading after the company said it would partner with GlaxoSmithKline PLC to use computing and artificial intelligence for drug discovery. “GSK is leading the industry in defining the next generation of data-driven drug discovery by harnessing genetic and clinical data to bring more precision to research and medicine,” Nvidia’s healthcare vice president Kimberly Powell said in a release. The companies will work together to “put vast data sources to work to advance the discovery of new medicines and vaccines,” she continued. Nvidia announced in a separate release that it was working to build the U.K.’s most powerful supercomputer, “which it will make available to U.K. healthcare researchers using AI to solve pressing medical challenges, including those presented by COVID-19.” These announcements come after Nvidia revealed in September that it plans to acquire British chip company Arm Ltd. from Softbank Group Corp. in a deal valued at $40 billion in cash and stock. Nvidia shares have gained 129% so far this year as the S&P 500 has risen 4.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.